Cirmtuzumab (UC-961), a first-in-class humanized anti-ROR1 mAb, had specific antitumor effect on CLL, breast cancer and pancreas ADC cancer without any off-target activity or toxicity in preclinical tests. This evidence concerns the gene ROR1 and breast cancer.